CHRU Jean Minjoz
- Address
- 3 boulevard Fleming, 25000 Besançon, France
CHRU Jean Minjoz - Rare Disease and Oncology Research Center
CHRU Jean Minjoz is a leading academic medical center engaged in specialized clinical research for rare and complex diseases. The institution demonstrates particular expertise in studying rare hematological disorders and pediatric oncology, with a focus on developing novel therapeutic interventions and optimizing treatment protocols for conditions with limited therapeutic options.
- Systemic mastocytosis research, including investigational treatments for smouldering and indolent severe forms
- Ewing sarcoma clinical trials, focusing on multimodal treatment approaches combining chemotherapy and radiotherapy
- Rare disease therapeutics and targeted molecular therapies
The center participates in international collaborative research networks, contributing to phase III randomized controlled trials that evaluate both novel targeted agents and optimized treatment regimens. Through their involvement in multicenter studies, CHRU Jean Minjoz plays a critical role in advancing therapeutic options for patients with rare hematologic malignancies and pediatric solid tumors, particularly those unresponsive to conventional symptomatic treatments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1The University Of Birmingham1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in CHRU Jean Minjoz
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Oral Masitinib Versus Placebo in Patients with Smouldering or Indolent Severe Systemic Mastocytosis Unresponsive to Symptomatic Treatment | Ab Science | Phase III | Not Recruiting | Nov 2025 | Jul 2026 |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 1 | Unknown | 2025-09-24 | 2025-09-24 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.